Gopal Parthasarathy

Data for Depletion forces from interacting crowders

Gopal Parthasarathy, Xiang Cheng, Kevin D. Dorfman

The data archived here includes all results from the post-processing analysis of molecular dynamics simulations, cluster analysis, and free energy calculations referenced in the attached paper titled "Depletion forces from interacting crowders." This dataset offers a reusable computational framework and data resource …

us (code pays fourni par la source)

Brownian dynamics simulations of telechelic polymer – latex suspensions under steady shear

Sriram Krishnamurthy, Gopal Parthasarathy, Ronald G. Larson, Ethayaraja Mani

on model latex paint formulations. The weakness of the shear thinning, relative to that of hydrophobically modified ethoxylated urethane (HEUR) solutions without colloids, is likely due to the observed insensitivity of the loop-to-bridge and bridge-to-loop transition times to the imposed shear rate. …

in, us (code pays fourni par la source)

Rheology of associative telechelic polymer - latex suspension

Ethayaraja Mani, Gopal Parthasarathy, Alyssa Travitz, Ronald G. Larson

From Screening to Targeted Degradation: Strategies for the Discovery and Optimization of Small Molecule Ligands for PCSK9

Whitney L. Petrilli, Gregory C. Adam, Roman S. Erdmann, Pravien D. Abeywickrema et autres

Identification of potent inhibitors of the sortilin-progranulin interaction

Shawn J. Stachel, Anthony T. Ginnetti, Scott Arne Johnson, Paige E. Cramer et autres

us (code pays fourni par la source)

Discovery of N-(Indazol-3-yl)piperidine-4-carboxylic Acids as RORγt Allosteric Inhibitors for Autoimmune Diseases

Hongjun Zhang, Blair T. Lapointe, Neville J. Anthony, Rita Azevedo et autres

The clinical success of anti-IL-17 monoclonal antibodies (i.e., Cosentyx and Taltz) has validated Th17 pathway modulation for the treatment of autoimmune diseases. The nuclear hormone receptor RORγt is a master regulator of Th17 cells and affects the production of a host of …

us, nl (code pays fourni par la source)

From Screening to Targeted Degradation: Strategies for the Discovery and Optimization of Small Molecule Ligands for PCSK9

Whitney L. Petrilli, Gregory C. Adam, Roman S. Erdmann, Pravien D. Abeywickrema et autres

us (code pays fourni par la source)

From Screening to Targeted Degradation: Strategies for the Discovery and Optimization of Small Molecule Ligands for PCSK9

Whitney L. Petrilli, Gregory C. Adam, Roman S. Erdmann, Pravien D. Abeywickrema et autres

Proprotein convertase substilisin-like/kexin type 9 (PCSK9) is a serine protease involved in a protein-protein interaction with the low-density lipoprotein (LDL) receptor that has both human genetic and clinical validation. Our pursuit of small molecule direct binders for this difficult to drug PPI …

us (code pays fourni par la source)

From Screening to Targeted Degradation: Strategies for the Discovery and Optimization of Small Molecule Ligands for PCSK9

Whitney L. Petrilli, Gregory C. Adam, Roman S. Erdmann, Pravien D. Abeywickrema et autres

Proprotein convertase substilisin-like/kexin type 9 (PCSK9) is a serine protease involved in a protein-protein interaction with the low-density lipoprotein (LDL) receptor that has both human genetic and clinical validation. Our pursuit of small molecule direct binders for this difficult to drug PPI …

us (code pays fourni par la source)

Indole acids as a novel PDE2 inhibitor chemotype that demonstrate pro-cognitive activity in multiple species

Shawn J. Stachel, Melissa S. Egbertson, Jenny Wai, Michelle R. Machacek et autres

us (code pays fourni par la source)

The identification of a novel lead class for phosphodiesterase 2 inhibition by fragment-based drug design

Ashley B. Forster, Pravien D. Abeywickrema, Jaime L. Bunda, Christopher D. Cox et autres

us (code pays fourni par la source)

Identification and in Vivo Evaluation of Liver X Receptor β-Selective Agonists for the Potential Treatment of Alzheimer’s Disease

Shawn J. Stachel, Celina Zerbinatti, Michael T. Rudd, Mali L. Cosden et autres

Herein, we describe the development of a functionally selective liver X receptor β (LXRβ) agonist series optimized for Emax selectivity, solubility, and physical properties to allow efficacy and safety studies in vivo. Compound 9 showed central pharmacodynamic effects in rodent models, evidenced …

us, cn (code pays fourni par la source)